The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for ...
This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.
Clinical Trials Arena on MSN
Structure Therapeutics announces positive results from aleniglipron trial
Aleniglipron showed a tolerability profile that is consistent with the GLP-1 receptor agonist class.
Going into next year, 42% of employers cited health care cost control for both the organization and its employees as their No ...
Stocktwits on MSN
The 2025 weight-loss drug gold rush: How Eli Lilly pulled ahead, Novo hit a snag — and a swarm of biotech underdogs are closing in
Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...
OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.
A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or ...
About one in eight adults say they are taking a GLP-1 receptor agonist as a treatment for obesity, diabetes or another ...
In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Industry experts ...
Since an investor revolt early this year at Air Products and Chemicals, the new leadership at the industrial gas giant has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback